Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Research & Development: 2017-2024

Historic Research & Development for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $111.6 million.

  • Kiniksa Pharmaceuticals International's Research & Development fell 7.26% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 1.04%. This contributed to the annual value of $111.6 million for FY2024, which is 46.69% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Research & Development stood at $111.6 million for FY2024, which was up 46.69% from $76.1 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Research & Development's 5-year high stood at $112.0 million during FY2020, with a 5-year trough of $65.5 million in FY2022.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Research & Development had a median value of $76.1 million in 2023 and averaged $84.4 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 34.05% in 2022, then surged by 46.69% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Research & Development (Yearly) stood at $112.0 million in 2020, then fell by 11.38% to $99.3 million in 2021, then tumbled by 34.05% to $65.5 million in 2022, then increased by 16.20% to $76.1 million in 2023, then soared by 46.69% to $111.6 million in 2024.